Search results
Added:
3 years ago
A bifurcation lesion within the coronary arterial circulation is defined as a stenosis occurring at, or adjacent to, a significant division of a major epicardial coronary artery.1 Bifurcation lesions account for 1–20% of all percutaneous coronary interventions (PCIs), and treatment remain technically challenging despite advances in PCI techniques and third-generation drug-eluting stent (DES)…
View more
Added:
1 year ago
In this short interview, Dr Matthew Mæng (Aarhus University Hospital, DK) joins us to discuss the outcomes of a follow-up study on OCT SORT-OUT VIII (NCT02253108), originally presented at EuroPCR 2022.
This follow-up study aimed to compare the outcomes of Boston Scientific's SYNERGY™ stent to the BioMatrix NeoFlex stent.
Findings suggest that the SYNERGY™ stent was non-inferior to the BioMatrix…
View more
Added:
11 months ago
Join Prof Nicolas Van Mieghem and Dr Joost Daemen, interventional experts from the Thoraxcenter at Erasmus MC in Rotterdam, as they provide a comprehensive preview of the late-breaking trials and studies that will be presented at EuroPCR 2023. In this dynamic episode, they offer valuable insights into the latest developments in interventional clinical and research science.
Studies include:…
View more
Added:
2 years ago
Dr Giulio Stefanini (Humanitas Research Hospital, Milan, IT) discusses the findings from the multicentre POEM trial.The trial assessed the safety of the bioresorbable polymer-coated everolimus-eluting Synergy® stent in CAD patients undergoing PCI, followed by 1-month dual antiplatelet therapy (DAPT) in patients at high bleeding risk (HBR).
Questions:
1. What is the POEM Study and what does it…
View more
Added:
3 years ago
First-generation Stents
Since drug-eluting stents (DES) received the CE mark in 2002 and the US Food and Drug Administration (FDA) approved the first DES in 2003, there has been a significant increase in the use of these devices. The advent of DES has revolutionised the field of interventional cardiology by having a major impact on patient care through their efficacy in reducing the need for…
View more
Added:
3 years ago
The introduction of coronary stents in the late 1980s improved outcome over balloon angioplasty via a reduction in acute vessel closure, prevention of vessel recoil, increase in acute gain and a lower rate of clinical restenosis.1,2 However, in-stent restenosis (ISR), caused by smooth-muscle cell proliferation and migration, leading to neointimal hyperplasia, remains the Achilles’ heel of bare…
View more
Added:
3 years ago
Newer generation polymeric metallic drug-eluting stents (DES) have shown improved efficacy and safety compared with bare-metal stents and first-generation DES, improving patient outcomes after percutaneous coronary intervention (PCI) and facilitating the treatment of more complex coronary disease.1 However, clinical outcomes in certain lesion and patient subsets remain suboptimal. Procedural and…
View more
Added:
3 years ago
Dual antiplatelet therapy (DAPT), defined as the use of a P2Y12 receptor inhibitor (clopidogrel, ticagrelor or prasugrel) and aspirin, is required after percutaneous coronary intervention (PCI) with drug-eluting stents (DES).1 Although the use of DES has been shown to reduce the rate of restenosis as compared with bare-metal stents (BMS), there is concern that DES may be associated with a higher…
View more
Added:
3 years ago
Approach to the Bifurcation Patient
Historically, bifurcation lesions have been associated with lower procedural success and a poorer clinical outcome than non-bifurcation lesions. This may be due to the technical difficulty of the procedure but also due to the complexity of the patients. According to the recently presented LEADERS trial sub-study,1 patients who have bifurcation disease are…
View more
Added:
3 years ago
Obstructive unprotected left main coronary artery (ULMCA) disease has been recognised as a high-risk condition since the 1960s owing to the large quantum of myocardium supplied by this system (see Figure 1). In that era, medical therapy was the only available management and 5-year mortality rates exceeded 60 %.1 With the introduction of coronary artery bypass grafting (CABG) it became clear that…
View more
